stockportfolio.pro
Stocks / ABT vs MRK
ABT vs MRK
Abbott Laboratories and Merck & Co., Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Abbott Laboratories (ABT) | Merck & Co., Inc. (MRK) | |
|---|---|---|
| Market cap | $154.4B | $283.8B |
| Revenue (latest FY) | $44.33B | $65.01B |
| Net income (latest FY) | $6.52B | $18.25B |
| Revenue growth (5y CAGR) | 5.1% | 9.4% |
| Net margin | 14.7% | 28.1% |
| Return on equity | 12.5% | 34.7% |
| P/E ratio | 24.7 | 32.4 |
| Dividend yield | 2.9% | 2.9% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABT — free Open MRK — freeFrequently asked questions
Which is bigger, ABT or MRK?
Merck & Co., Inc. is larger by market capitalization — $283.8B versus $154.4B.
Which grows faster, ABT or MRK?
Over the last five fiscal years, Merck & Co., Inc. grew revenue faster — 9.4%/yr versus 5.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.